Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus
El-Rifaie, A., Rashed, L., Abdellatif, M., Mohamed, A. (2022). Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus. EKB Journal Management System, 3(3), 105-116. doi: 10.21608/ejmr.2022.254009
Abd-El Aziz El-Rifaie; Laila Ahmed Rashed; Mona El sayed Ahmed Abdellatif; Asmaa Abdel Ghany Mohamed. "Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus". EKB Journal Management System, 3, 3, 2022, 105-116. doi: 10.21608/ejmr.2022.254009
El-Rifaie, A., Rashed, L., Abdellatif, M., Mohamed, A. (2022). 'Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus', EKB Journal Management System, 3(3), pp. 105-116. doi: 10.21608/ejmr.2022.254009
El-Rifaie, A., Rashed, L., Abdellatif, M., Mohamed, A. Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus. EKB Journal Management System, 2022; 3(3): 105-116. doi: 10.21608/ejmr.2022.254009

Detection of Desmoglein-3 Auto-Antibodies in Patients with Lichen Planus

Egyptian Journal of Medical Research
Volume 3, Issue 3, July 2022, Page 105-116  XML PDF (523.49 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.254009
View on SCiNiTO View on SCiNiTO
Authors
Abd-El Aziz El-Rifaie1; Laila Ahmed Rashed2; Mona El sayed Ahmed Abdellatif1; Asmaa Abdel Ghany Mohamed1
1Dermatology Department-Faculty of Medicine, Beni-Suef University.
2Professor of Biochemistry-Faculty of Medicine, Cairo University.
Abstract
There is controversy about the role of auto anti-bodies against desmoglein 3 (Dsg 3) in the pathogenesis of lichen planus (LP). The goal of this study is to detect desmoglein-3 auto-antibodies in lichen planus patients comparted to normal control persons via investigating its potential role in the pathogenesis of this disease. A case control study for detection of Desmoglein-3 autoantibodies in serum of 40 lichen planus patients and 40 healthy controls using enzyme-linked immunosorbent assay (ELISA) technique.The patients and healthy controls were recruited from Dermatology outpatient clinic at Beni-Suef University hospital. The measurement of anti Dsg3 antibodies in LP patients was significantly higher as compared to normal control persons. The mean scores were 1361.37 ± 300.5 in oral LP & 2118.70 ± 584.37 in cutaneous LP vs. 66.98 ±70.95 in controls (p-value < 0.001). Desmoglein-3 auto-antibodies in LP may have a role in the pathogenesis of the disease. Further investigations are needed for detection of Dsg 3 auto-antibodies in LP skin biopsy or blood samples by other methods such as Immunofluorescence.
Keywords
lichen planus; Dsg3; Autoantibody
References
  1. Shiohara T, Kano Y. (2008): Lichen Planus and Lichenoid Dermatoses: Bolognia: Dermatology, 2nd ed. Chapter 12, pp: 159- 70.
  2. .Roopashree MR, Shashikanth MC, George J, Thippeswamy SH, et al. (2010): Pathogenesis of oral lichen planus: a review. Journal of Oral Pathology & Medicine. Vol. 39, no. 10, pp: 729-34.
  3. Wu KM, Wang YP, Lin HP, et al.(2013): Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus. J Formos Med Assoc 2013; 112: 352-357.
  4. Piccinni, M. P., Lombardelli, L., Logiodice, F., Tesi, D., Kullolli, O., Biagiotti, R., ... & Ficarra, G. (2014): Potential pathogenetic role of Th17, Th0, Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral diseases, 20(2), 212-218.
  5. Xie S, Ding L, Xiong Z, Zhu S (2012): Implications of Th1 and Th17 cells in pathogenesis of oral lichen planus. J Huazhong Univ Sci Technolog Med Sci 32: 451-457.
  6. Vahide, L., Zahra, H., Forugh, G., & Nazi, S. (2017): Autoantibodies to desmogleins 1 and 3 in patients with lichen planus. Archives of dermatological research, 309(7), 579-583.
  7. Knapp RG, Miller MC. (1992): Clinical epidemiology and biostatistics. Published by Williams & Wilkins; Malvern, Pa: Harwal Pub. Co., C.
  8. Shiohara T, Kano Y, Jean L (2012): Lichen planus and lichenoid dermatoses. In: Bolognia JL, Jorizzo JL, Schaffer JV (eds) Der- mathology, 3rd edn. Saunders/Elsevier, New York, p 192.
  9. Sugerman PB, Savage NW. and Walsh LJ. (2002): The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. Vol. 13, no. 8, pp: 350-65.
  10. Muramatsu K, Nishie W, Natsuga K, Fujita Y, Iwata H, Yamada T, Yamashita E, Asaka T, Shimizu H (2016): Two cases of erosive oral lichen planus with autoantibodies to desmoglein 3. J Der- matol 43(11):1350-1353.
  11. Herrero-Gonza´lez JE, Parera Amer E, Segura S, Mas Bosch V, Pujol RM, Mart´ınez Escala ME (2016): Epithelial antigenic specificities of circulating autoantibodies in mucosal lichen pla- nus. Int J Dermatol 55(6):634–639.
  12. Gholizadeh, N., Poorfar, H.K., TaghaviZenouz, A., Vatandoost, M. and Mehdipour, M., 2015. Comparison of serum autoantibodies to desmogleins I, III in patients with oral lichen planus and healthy controls. Iranian journal of pathology, 10(2), p.136.
  13. Lukac J, Brozovi'c S, Vucicevi'c-Boras V, et al.(2006): Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus. Croat Med J 2006; 47: 53-58.
  14. Kinjyo C, Kaneko T, Korekawa A, Rokunohe A, Aizu T, Mat- suzaki Y, Nakano H, Sawamura D (2015): Oral lichen planus with antibodies to desmogleins 1 and 3. J Dermatol 42(1):40-41.
  15. Kishimoto K, Konno Y, Nakamura K, Kaneko F (2005): A case of oral lichen planus showing antibodies for desmoglein 1 and BP180 NC16a. Rinsho Derma 47:741-744.
  16. Munde, A. D., Karle, R. R., Wankhede, P. K., Shaikh, S. S., & Kulkurni, M. (2013): Demographic and clinical profile of oral lichen planus: A retrospective study. Contemporary clinical dentistry, 4(2), 181.
  17. Kato T, Fujimoto N, Uenishi T, Tanaka T (2009): A case of oral lichen planus in a patient with anti-desmoglein antibodies. Skin Res 8:173-176.
  18. Rambhia, K., Kharkar, V., Pradhan, V., Patwardhan, M., Ghosh, K. and Khopkar, U., 2018. A study of prevalence of autoantibodies in patients with lichen planus from Mumbai, India. Indian journal of dermatology, venereology and leprology, 84(6), pp.667-671.
  19. Shimokata-Isoe, M., Hashimoto, T., Hirose, M., Shinada, Y., Matsuo, S., Munetsugu, T., Koga, H., Ishii, N. and Satoh, T., 2021. Distinguishing paraneoplastic pemphigus with keratotic skin lesions lacking anti-plakin antibodies from severe lichen planus. European Journal of Dermatology, 1.
  20. Solimani, F., Pollmann, R., Schmidt, T., Schmidt, A., Zheng, X., Savai, R., Mühlenbein, S., Pickert, J., Eubel, V., Möbs, C. and Eming, R., 2019. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Frontiers in immunology, 10, p.1808.
  21. Shao, S., Tsoi, L.C., Sarkar, M.K., Xing, X., Xue, K., Uppala, R., Berthier, C.C., Zeng, C., Patrick, M., Billi, A.C. and Fullmer, J., 2019. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Science translational medicine, 11(511).
  22. Pietschke, K., Holstein, J., Meier, K., Schäfer, I., Müller‐Hermelink, E., Gonzalez‐Menendez,I.,Quintanilla‐Martinez, L., Ghoreschi, F.C., Solimani, F. and Ghoreschi, K., 2021. The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition. Experimental Dermatology, 30(2), pp.262-270.
Statistics
Article View: 177
PDF Download: 102